- Home
- MLP vs ERAS Comparison
MLP vs ERAS Comparison
Compare MLP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLP
- ERAS
- Stock Information
- Founded
- MLP 1909
- ERAS 2018
- Country
- MLP United States
- ERAS United States
- Employees
- MLP N/A
- ERAS N/A
- Industry
- MLP Real Estate
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- MLP Finance
- ERAS Health Care
- Exchange
- MLP Nasdaq
- ERAS Nasdaq
- Market Cap
- MLP 344.7M
- ERAS 348.4M
- IPO Year
- MLP 1972
- ERAS 2021
- Fundamental
- Price
- MLP $17.27
- ERAS $1.46
- Analyst Decision
- MLP
- ERAS Strong Buy
- Analyst Count
- MLP 0
- ERAS 6
- Target Price
- MLP N/A
- ERAS $4.83
- AVG Volume (30 Days)
- MLP 21.4K
- ERAS 1.2M
- Earning Date
- MLP 08-18-2025
- ERAS 08-11-2025
- Dividend Yield
- MLP N/A
- ERAS N/A
- EPS Growth
- MLP N/A
- ERAS N/A
- EPS
- MLP N/A
- ERAS N/A
- Revenue
- MLP $14,886,000.00
- ERAS N/A
- Revenue This Year
- MLP N/A
- ERAS N/A
- Revenue Next Year
- MLP N/A
- ERAS N/A
- P/E Ratio
- MLP N/A
- ERAS N/A
- Revenue Growth
- MLP 57.13
- ERAS N/A
- 52 Week Low
- MLP $14.05
- ERAS $1.01
- 52 Week High
- MLP $26.46
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- MLP 48.15
- ERAS 50.74
- Support Level
- MLP $17.18
- ERAS $1.38
- Resistance Level
- MLP $18.58
- ERAS $1.58
- Average True Range (ATR)
- MLP 0.74
- ERAS 0.11
- MACD
- MLP -0.12
- ERAS 0.01
- Stochastic Oscillator
- MLP 20.09
- ERAS 59.46
About MLP Maui Land & Pineapple Company Inc.
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.